In the United States, a rare disease is defined as one that impacts fewer than 200,000 individuals, and in the European Union, a disease is considered rare if it affects fewer than 1 in 2,000 people. Around 7,000 rare diseases have been identified, with Guillain-Barré Syndrome being one of them.
Guillain-Barré Syndrome (GBS) is a condition in which a person's immune system attacks the peripheral nerves. The nerve damage progresses rapidly, causing acute neuromuscular paralysis, and can lead to significant morbidity, disability, and even death. Every year, 22,000 people in the U.S. and Europe are hospitalized with GBS. Currently, there are no approved treatments for this condition in the U.S. Intravenous Immunoglobulin (IVIg) is used off-label to treat GBS.
For comments and feedback: editorial@rttnews.com